Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

View source version on?businesswire.com:?https://www.businesswire.com/news/home/20210805005259/en/
Investor DeDe Sheel 415.732.9828 dsheel@sierraoncology.com Media Lauren Musto 615.351.7777 lmusto@sierraoncology.com Source: Sierra Oncology